CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG ...

The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright ...

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...

Detailed price information for Ark Innovation ETF (ARKK-A) from The Globe and Mail including charting and trades.

What you need to know about Ark Invest, an active ETF firm led by Cathie Wood that invests in disruptive, high-growth tech ...

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are ...